Specifically, we included two drugs that are currently used in clinical chemotherapy as first line treatment for pancreatic cancer (Gemcitabine and Oxaliplatin), seven drugs that have specific kinase targets which play key roles in different pathways (i.e., IKK, MEK, JAK, PI3K, EGFR, AKT and PDPK1 inhibitors) and one cytokine (TNFα) that activates the extrinsic apoptosis pathway. The gene discussed is AKT1; the disease is familial pancreatic carcinoma.